Ann: Positive IHL-675A in vivo results and FDA Pathway, page-60

Thanks Exalted , anecdotal or not that is a further indication of how well the company is run and to secure the quality of consultants they have to date . I agree I was also unaware of Camargo until now . Given the application of a successful drug is universal it makes sense to retain consultants with such credentials and that has a relationship with the FDA .

Moreover the BOD is targeting products which if successful have worldwide application and so they need a world stage and so they retain world renowned consultants to deliver that . Big pharma will stand up and have no choice but to take notice of the potential applications of the product .
Australia is a small market and on successful FDA approval the markets will be USA and Europe

I am really excited here .